At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 72 enrolled
Drug / intervention
LY3022855 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1a/1b Trial Investigating the CSF-1R Inhibitor LY3022855 in Combination With Durvalumab (MEDI4736) or Tremelimumab in Patients With Advanced Solid Tumors
In Brief
A Phase 1 clinical trial evaluating LY3022855, Durvalumab, and 1 other intervention for Solid Tumor. Completed, enrolled 72 participants across 14 sites in 4 countries.
Detailed Summary
The main purpose of this study is to evaluate the safety of the colony-stimulating factor 1 receptor (CSF-1R) inhibitor LY3022855 in combination with durvalumab or tremelimumab in participants with advanced solid tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumor
CountriesBelgium, Czechia, Israel, United States
CollaboratorsAstraZeneca
Timeline
Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedMar 2016
Enrollment StartJun 2016
Primary CompletionDec 2018
TodayJul 2026
First PostedMar 24, 2016
Enrollment StartJun 16, 2016
Primary CompletionDec 14, 2018
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 10.3 years ago
Interventions
LY3022855drug
Administered IV
Durvalumabdrug
Administered IV
Tremelimumabdrug
Administered IV